Antimicrobial De-escalation Rates following Positive Cultures in Pneumonia. (4th October 2017)
- Record Type:
- Journal Article
- Title:
- Antimicrobial De-escalation Rates following Positive Cultures in Pneumonia. (4th October 2017)
- Main Title:
- Antimicrobial De-escalation Rates following Positive Cultures in Pneumonia
- Authors:
- Deshpande, Abhishek
Richter, Sandra S
Haessler, Sarah
Brizendine, Kyle
Lindenauer, Peter
Yu, Pei-Chun
Zilberberg, Marya D
Imrey, Peter
Higgins, Thomas
Rothberg, Michael - Abstract:
- Abstract: Background: For patients at risk for multidrug resistant organisms, the recommended empirical therapy includes 1 agent against methicillin-resistant S. aureus (MRSA) and 1 against Pseudomonas . Guidelines recommend de-escalation following positive cultures but it is unclear how often this recommendation is followed. We assessed the rate of de-escalation among a large cohort of pneumonia patients. Methods: We included adults admitted with pneumonia 2010- 2015 to 168 US hospitals if they had blood/respiratory cultures obtained and received empiric vancomycin together with an antipseudomonal drug other than a quinolone by hospital day 1. Patients who died or were discharged before hospital day 4 were excluded. De-escalation for a cultured Gram-positive organism (which should not require antipseudomonal coverage) was defined as discontinuation of the antipseudomonal drug and for a Gram-negative organism (which should not require vancomycin) as discontinuation of vancomycin by hospital day 4, while continuing another antibiotic in either case. We compared de-escalation rates following positive cultures to those following negative cultures. Results: We identified 29, 333 patients who met inclusion criteria. Of the patients with positive cultures (4415), 53% had a Gram-positive and 47% a Gram-negative organism. Antipseudomonals were stopped by hospital day 4 more often following identification of a Gram-positive organism than following negative cultures (44% vs. 26%, P <Abstract: Background: For patients at risk for multidrug resistant organisms, the recommended empirical therapy includes 1 agent against methicillin-resistant S. aureus (MRSA) and 1 against Pseudomonas . Guidelines recommend de-escalation following positive cultures but it is unclear how often this recommendation is followed. We assessed the rate of de-escalation among a large cohort of pneumonia patients. Methods: We included adults admitted with pneumonia 2010- 2015 to 168 US hospitals if they had blood/respiratory cultures obtained and received empiric vancomycin together with an antipseudomonal drug other than a quinolone by hospital day 1. Patients who died or were discharged before hospital day 4 were excluded. De-escalation for a cultured Gram-positive organism (which should not require antipseudomonal coverage) was defined as discontinuation of the antipseudomonal drug and for a Gram-negative organism (which should not require vancomycin) as discontinuation of vancomycin by hospital day 4, while continuing another antibiotic in either case. We compared de-escalation rates following positive cultures to those following negative cultures. Results: We identified 29, 333 patients who met inclusion criteria. Of the patients with positive cultures (4415), 53% had a Gram-positive and 47% a Gram-negative organism. Antipseudomonals were stopped by hospital day 4 more often following identification of a Gram-positive organism than following negative cultures (44% vs. 26%, P < 0.001). Similarly, vancomycin was stopped by hospital day 4 more often after a Gram-negative organism was cultured than when no organism was identified (66% vs. 49%, P < 0.001). Conclusion: In a large US inpatient database, de-escalation was more common following positive cultures than negative cultures. De-escalation was most common following growth of Gram-negative organisms. There remains substantial opportunity for improvement in antibiotic de-escalation. Disclosures: S. S. Richter, bioMerieux: Investigator, Research support; BD Diagnostics: Investigator, Research support; Roche: Investigator, Research support; BioFire: Investigator, Research support; OpGen: Investigator, Research support; S. Haessler, AHRQ: Investigator, Research grant; P. C. Yu, AHRQ: Investigator, Research grant; M. D. Zilberberg, Astellas: Consultant and Investigator, Research support; Merck: Consultant and Investigator, Research support; The Medicines Company: Consultant and Investigator, Research support; Shionogi: Consultant and Investigator, Research support; Pfizer: Consultant and Investigator, Research support; Theravance: Consultant and Investigator, Research support; J&J: Shareholder, Shareholder; M. Rothberg, AHRQ: Investigator, Research grant … (more)
- Is Part Of:
- Open forum infectious diseases. Volume 4(2017)Supplement 1
- Journal:
- Open forum infectious diseases
- Issue:
- Volume 4(2017)Supplement 1
- Issue Display:
- Volume 4, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 4
- Issue:
- 1
- Issue Sort Value:
- 2017-0004-0001-0000
- Page Start:
- S569
- Page End:
- S569
- Publication Date:
- 2017-10-04
- Subjects:
- Communicable diseases -- Periodicals
Medical microbiology -- Periodicals
Infection -- Periodicals
616.9 - Journal URLs:
- http://ofid.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/ofid/ofx163.1486 ↗
- Languages:
- English
- ISSNs:
- 2328-8957
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21120.xml